Pfizer Names New Head of Clinical Development and Medical Affairs for Its Oncology Business Unit

27-Oct-2008 - USA

Pfizer announced that it has named Mace L. Rothenberg, M.D. as Senior Vice President, Clinical Development and Medical Affairs for its oncology Business Unit. Dr. Rothenberg comes to Pfizer from Vanderbilt where he was Professor of medicine at the Vanderbilt University Medical Center and Ingram Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center.

In his new role, Dr. Rothenberg will be responsible for overseeing clinical research and development activities as well as post-marketing evaluation and monitoring for all oncology products. He will also coordinate evaluation of anticancer compounds that emerge from Pfizer’s new Biotechnology and Bioinnovation Center as well as evaluate potential in-licensed products from outside sources.

Dr. Rothenberg has been active in clinical-translational research in oncology for more than 20 years. He has been the recipient of several research grants from the National Cancer Institute and has served as a reviewer on several NIH study sections. According to the company, Dr. Rothenberg’s work was critical to the development and eventual FDA approval of irinotecan (CPT-11, Camptosar®) in 1996 and oxaliplatin (Eloxatin®) in 2002 for colorectal cancer and gemcitabine (Gemzar®) in 1996 for pancreatic cancer.

Dr. Rothenberg received his B.A. from the University of Pennsylvania magna cum laude in 1978, his M.D. from the New York University School of Medicine in 1982, and trained as an Intern and Resident in Internal Medicine at Vanderbilt University from 1982 to 1985. He obtained his medical oncology training at the National Cancer Institute from 1985 to 1988 and served as Special Assistant to the Director, Division of Cancer Treatment from 1988 to 1991. In 1991, he moved to San Antonio where he was appointed Assistant, then Associate Professor in the Department of Medicine, Division of Medical Oncology at the University of Texas Health Science Center in San Antonio and Executive Officer of the Southwest Oncology Group. In 1998, Dr. Rothenberg returned to Vanderbilt where he is currently Professor of Medicine, Ingram Professor of Cancer Research, Director of Phase I Drug Development, Co-Leader of the Experimental Therapeutics Program, and Co-Principal Investigator of the Vanderbilt SPORE in Gastrointestinal Cancer.

https://www.bionity.com/en/news/88611/pfizer-names-new-head-of-clinical-development-and-medical-affairs-for-its-oncology-business-unit.html